CervoMed completes enrollment in Phase 2a study of neflamapimod for nfvPPA

CervoMed Inc.

Enrolled 25 participants; interim biomarker data to be presented at CTAD conference Nov 16-19, 2026.
First clinical data expected in Q1 2027; study includes 24-week treatment plus 12-week placebo-controlled extension.
Nature Neuroscience publication shows p38α inhibition rescues axonal transport deficits in tau-related FTD models.
No approved treatments for nfvPPA in US or EU; neflamapimod granted Orphan Drug Designation for FTD in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.